Akari Therapeutics Plc (AKTX) News

Akari Therapeutics Plc (AKTX): $1.13

0.04 (+3.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 496

in industry

Filter AKTX News Items

AKTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AKTX News Highlights

  • For AKTX, its 30 day story count is now at 2.
  • Over the past 16 days, the trend for AKTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about AKTX are AB, BIO and LUNG.

Latest AKTX News From Around the Web

Below are the latest news stories about Akari Therapeutics Plc that investors may wish to consider to help them evaluate AKTX as an investment opportunity.

Akari Therapeutics to Present at BIO CEO & Investor Conference

NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer of Akari Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:30 p.m. ET,

Yahoo | February 11, 2022

Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

NEW YORK and LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced further development of a program for the inhaled delivery of nomacopan to the lung, working with Inhalation Sciences AB to refine dosing and pharmacokinetics of nomacopan for both dry powder

Yahoo | January 26, 2022

Akari says FDA agrees to use of new manufacturing process for nomacopan for trials

Akari Therapeutics <> said the U.S. Food and Drug Administration ((FDA)) agreed to the clinical use of nomacopan derived from a next generation manufacturing process.Nomacopan,…

Seeking Alpha | January 19, 2022

FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and commercializationNEW YORK and LONDON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. F

Yahoo | January 19, 2022

Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present a Company overview at the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. The pre-recorded presen

Yahoo | January 4, 2022

Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive agreements with institutional investors and accredited investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company’s

Yahoo | December 30, 2021

Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Above 50 Day Moving Average of $1.62

Akari Therapeutics, Plc (NASDAQ:AKTX)s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.62 and traded as high as $1.64. Akari Therapeutics shares last traded at $1.54, with a volume of 75,065 shares traded. The company has a market cap of $73.30 million, []

Dakota Financial News | December 24, 2021

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | December 5, 2021

Akari Therapeutics reports Q3 results

No summary available.

Seeking Alpha | December 3, 2021

Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress

NEW YORK and LONDON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the third quarter of 2021 and recent clinical progress.

Intrado Digital Media | December 3, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.465 seconds.